---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-26-000070"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2026-07-30T20:07:47+00:00"
generated_at: "2026-07-30T20:09:47.301331+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics Q2 revenue down 11% to $190.7M; revises FY2026 guidance lower, suspends EBITDA guidance

## Summary
- Q2 revenue $190.7M (-11% YoY); test volumes 379K flat; avg revenue per test down 9% including $11M prior-period estimate adjustment.
- Gross margin 66.6% (-460 bps); operating loss $38.9M; cash $115.2M.
- FY2026 revenue guidance revised to $770-790M; adjusted gross margin 66-67%; suspended Adjusted EBITDA guidance.
- Cancer Care Continuum volume up 6% but revenue down 11%; Prenatal Health volume down 9%; Mental Health volume up 4% but revenue down 3%.
- Launched Ascend efficiency initiative; evaluating portfolio; launched Prolaris+AI and FirstGene prenatal screen.

## SEC filing metadata
- accession: 0000899923-26-000070
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2026-07-30T20:07:47+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992326000070/0000899923-26-000070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992326000070/mygn-20260730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-26-000070
- JSON: https://secwatch.observer/filing/0000899923-26-000070.json
- Plain text: https://secwatch.observer/filing/0000899923-26-000070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.